Clinical Trial Update: Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers [EARLY_Phase 1]

View source ↗

Summary

A Vanderbilt University EARLY_PHASE1 trial evaluated whether low-dose aspirin inhibits COX-2–derived PGE2 in male smokers. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• Aspirin (low-dose) (acetylsalicylic acid)

Snippet

Sponsor: Vanderbilt University | Conditions: Tobacco Use Disorder, Smoking | EARLY_Phase 1 | Status: COMPLETED